These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 31996461)
1. Activation of Dendritic Cells Alters the Mechanism of MHC Class II Antigen Presentation to CD4 T Cells. Cho KJ; Ishido S; Eisenlohr LC; Roche PA J Immunol; 2020 Mar; 204(6):1621-1629. PubMed ID: 31996461 [TBL] [Abstract][Full Text] [Related]
2. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. Dolan BP; Gibbs KD; Ostrand-Rosenberg S J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172 [TBL] [Abstract][Full Text] [Related]
3. Strategy for identifying dendritic cell-processed CD4+ T cell epitopes from the HIV gag p24 protein. Bozzacco L; Yu H; Dengjel J; Trumpfheller C; Zebroski HA; Zhang N; Küttner V; Ueberheide BM; Deng H; Chait BT; Steinman RM; Mojsov S; Fenyö D PLoS One; 2012; 7(7):e41897. PubMed ID: 22860026 [TBL] [Abstract][Full Text] [Related]
4. Presentation by recycling MHC class II molecules of an influenza hemagglutinin-derived epitope that is revealed in the early endosome by acidification. Sinnathamby G; Eisenlohr LC J Immunol; 2003 Apr; 170(7):3504-13. PubMed ID: 12646611 [TBL] [Abstract][Full Text] [Related]
5. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells. Schnell S; Young JW; Houghton AN; Sadelain M J Immunol; 2000 Feb; 164(3):1243-50. PubMed ID: 10640737 [TBL] [Abstract][Full Text] [Related]
6. CD9 Regulates Major Histocompatibility Complex Class II Trafficking in Monocyte-Derived Dendritic Cells. Rocha-Perugini V; Martínez Del Hoyo G; González-Granado JM; Ramírez-Huesca M; Zorita V; Rubinstein E; Boucheix C; Sánchez-Madrid F Mol Cell Biol; 2017 Aug; 37(15):. PubMed ID: 28533221 [TBL] [Abstract][Full Text] [Related]
7. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design. Herrera OB; Brett S; Lechler RI Vaccine; 2002 Dec; 21(3-4):231-42. PubMed ID: 12450698 [TBL] [Abstract][Full Text] [Related]
8. Disruption of multivesicular body vesicles does not affect major histocompatibility complex (MHC) class II-peptide complex formation and antigen presentation by dendritic cells. Bosch B; Berger AC; Khandelwal S; Heipertz EL; Scharf B; Santambrogio L; Roche PA J Biol Chem; 2013 Aug; 288(34):24286-92. PubMed ID: 23846690 [TBL] [Abstract][Full Text] [Related]
9. Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming. Schlecht G; Loucka J; Najar H; Sebo P; Leclerc C J Immunol; 2004 Nov; 173(10):6089-97. PubMed ID: 15528345 [TBL] [Abstract][Full Text] [Related]
10. The invariant chain transports TNF family member CD70 to MHC class II compartments in dendritic cells. Zwart W; Peperzak V; de Vries E; Keller AM; van der Horst G; Veraar EA; Geumann U; Janssen H; Janssen L; Naik SH; Neefjes J; Borst J J Cell Sci; 2010 Nov; 123(Pt 21):3817-27. PubMed ID: 20971706 [TBL] [Abstract][Full Text] [Related]
11. MHC class II presentation is controlled by the lysosomal small GTPase, Arl8b. Michelet X; Garg S; Wolf BJ; Tuli A; Ricciardi-Castagnoli P; Brenner MB J Immunol; 2015 Mar; 194(5):2079-88. PubMed ID: 25637027 [TBL] [Abstract][Full Text] [Related]
12. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. Inaba K; Turley S; Iyoda T; Yamaide F; Shimoyama S; Reis e Sousa C; Germain RN; Mellman I; Steinman RM J Exp Med; 2000 Mar; 191(6):927-36. PubMed ID: 10727455 [TBL] [Abstract][Full Text] [Related]
13. Influenza A virus infection-induced macroautophagy facilitates MHC class II-restricted endogenous presentation of an immunodominant viral epitope. Deng J; Lu C; Liu C; Oveissi S; Fairlie WD; Lee EF; Bilsel P; Puthalakath H; Chen W FEBS J; 2021 May; 288(10):3164-3185. PubMed ID: 33830641 [TBL] [Abstract][Full Text] [Related]
14. Major histocompatibility complex (MHC) class II-peptide complexes arrive at the plasma membrane in cholesterol-rich microclusters. Bosch B; Heipertz EL; Drake JR; Roche PA J Biol Chem; 2013 May; 288(19):13236-42. PubMed ID: 23532855 [TBL] [Abstract][Full Text] [Related]
15. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation. Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164 [TBL] [Abstract][Full Text] [Related]
16. Ubiquitination by March-I prevents MHC class II recycling and promotes MHC class II turnover in antigen-presenting cells. Cho KJ; Walseng E; Ishido S; Roche PA Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10449-54. PubMed ID: 26240324 [TBL] [Abstract][Full Text] [Related]
17. Dendritic cells regulate exposure of MHC class II at their plasma membrane by oligoubiquitination. van Niel G; Wubbolts R; Ten Broeke T; Buschow SI; Ossendorp FA; Melief CJ; Raposo G; van Balkom BW; Stoorvogel W Immunity; 2006 Dec; 25(6):885-94. PubMed ID: 17174123 [TBL] [Abstract][Full Text] [Related]
18. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains. Machy P; Serre K; Baillet M; Leserman L J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652 [TBL] [Abstract][Full Text] [Related]
19. Distribution of productive antigen-processing activity for MHC class II presentation in macrophages. von Delwig A; Musson JA; Shim HK; Lee JJ; Walker N; Harding CV; Williamson ED; Robinson JH Scand J Immunol; 2005 Sep; 62(3):243-50. PubMed ID: 16179011 [TBL] [Abstract][Full Text] [Related]
20. Activation of human CD4+ T cells by targeting MHC class II epitopes to endosomal compartments using human CD1 tail sequences. Niazi KR; Ochoa MT; Sieling PA; Rooke NE; Peter AK; Mollahan P; Dickey M; Rabizadeh S; Rea TH; Modlin RL Immunology; 2007 Dec; 122(4):522-31. PubMed ID: 17635609 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]